Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 2 entities : I-mab save search
HI-Bio Announces Positive Phase 2 Data on Felzartamab for the Treatment of Primary Membranous Nephropathy
Published: 2023-04-11 (Crawled : 10:00) - prnewswire.com
IMAB | $1.8 160K
|
Health Technology
|
| O: 0.0%
H: 4.2%
C: 3.08%
nephropathy positive treatment phase 2
I-Mab Announces Positive Phase 2 Data of Lemzoparlimab in Combination with Azacitidine (AZA) in Patients with Higher Risk Myelodysplastic Syndrome at ESMO 2022
Published: 2022-09-10 (Crawled : 16:20) - prnewswire.com
IMAB | $1.8 160K
|
Health Technology
| Email alert
Add to watchlist
risk positive phase 2
I-Mab Announces Oral Presentation of Phase 2 Clinical Data of CD47 Antibody Lemzoparlimab at ESMO Congress 2022
Published: 2022-09-06 (Crawled : 18:00) - biospace.com/
IMAB | $1.8 160K
|
Health Technology
|
| O: 0.17%
H: 0.68%
C: -5.57%
cd47 antibody presentation phase 2
I-Mab to Present Phase 2 Clinical Data of CD47 Antibody Lemzoparlimab at ESMO Congress 2022
Published: 2022-07-18 (Crawled : 14:00) - biospace.com/
IMAB | $1.8 160K
|
Health Technology
|
| O: 1.12%
H: 6.39%
C: 2.76%
cd47 antibody phase 2
I-Mab to Hold Investor Call to Report Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab
Published: 2022-05-19 (Crawled : 19:00) - biospace.com/
IMAB | $1.8 160K
|
Health Technology
|
| O: -0.66%
H: 5.72%
C: 1.84%
cd73 report antibody phase 2
I-Mab Announces First Patient Dosed in China Phase 2 Combination Trial of Lemzoparlimab with Toripalimab in Patients with Advanced Solid Tumors
Published: 2022-01-18 (Crawled : 15:00) - biospace.com/
IMAB | $1.8 160K
|
Health Technology
|
| O: -8.6%
H: 5.62%
C: 2.83%
phase 2 solid tumors trial china
I-Mab Announces First Patient Dosed in China Phase 2 Clinical Trial of Efineptakin Alfa in Combination with Pembrolizumab in Advanced Solid Tumors
Published: 2022-01-12 (Crawled : 14:00) - biospace.com/
IMAB | $1.8 160K
|
Health Technology
|
| O: -0.02%
H: 0.0%
C: 0.0%
phase 2
I-Mab Announces IND Approval from China NMPA for Phase 2 Clinical Trial of Enoblituzumab in Combination with Pembrolizumab in Solid Tumors
Published: 2021-12-27 (Crawled : 14:00) - biospace.com/
MGNX | $16.45 6.75% 340K
|
Health Technology
|
| O: -0.75%
H: 1.28%
C: -2.84%
IMAB | $1.8 160K
|
Health Technology
|
| O: -0.49%
H: 2.25%
C: -0.79%
phase 2 solid tumors trial approval china
I-Mab Receives IND Approval for Phase 1 Clinical Trial of Bispecific Antibody TJ-CD4B in Solid Tumors in China
Published: 2021-12-15 (Crawled : 15:30) - biospace.com/
IMAB | $1.8 160K
|
Health Technology
|
| O: -11.41%
H: 8.08%
C: 7.32%
solid tumors trial approval phase 1 china antibody phase 2
I-Mab Announces First Patient Dosed in U.S. Phase 1 Study of Protollin for the Treatment of Alzheimer's Disease
Published: 2021-12-08 (Crawled : 14:00) - biospace.com/
IMAB | $1.8 160K
|
Health Technology
|
| O: 1.36%
H: 6.04%
C: 4.0%
alzheimer treatment disease phase 1 phase 2 alzheimer’s alzheimer's disease alzheimer's
I-Mab Announces First Two Patients Dosed in U.S. Phase 2 Combination Trial of Uliledlimab with Atezolizumab in Patients with Selected Advanced Solid Tumors
Published: 2021-12-03 (Crawled : 13:30) - biospace.com/
IMAB | $1.8 160K
|
Health Technology
|
| O: -5.2%
H: 0.0%
C: 0.0%
phase 2 solid tumors trial
MorphoSys AG: First Patient Dosed in Phase 2 IGNAZ Study of Felzartamab in Patients with Immunoglobulin A Nephropathy
Published: 2021-10-20 (Crawled : 23:00) - biospace.com/
MOR | News | $17.965 0.03% 150K
|
Health Technology
|
| O: 0.0%
H: 0.88%
C: -0.79%
IMAB | $1.8 160K
|
Health Technology
|
| O: 0.2%
H: 3.08%
C: 0.91%
phase 2 nephropathy
I-Mab Announces IND Approval for Phase 2 Clinical Trial of Efineptakin Alfa in Combination with PD-1 Therapy in China
Published: 2021-10-18 (Crawled : 12:00) - prnewswire.com
IMAB | $1.8 160K
|
Health Technology
|
| O: -1.19%
H: 4.34%
C: 2.66%
phase 2 china therapy trial approval
I-Mab Announces Acceptance of IND Application from China NMPA for Phase 2 Clinical Trial of Enoblituzumab in Combination with Pembrolizumab in Solid Tumors
Published: 2021-09-28 (Crawled : 14:00) - biospace.com/
MGNX | $16.45 6.75% 340K
|
Health Technology
|
| O: -1.31%
H: 2.55%
C: 1.03%
IMAB | $1.8 160K
|
Health Technology
|
| O: 5.74%
H: 1.23%
C: -6.32%
phase 2 solid tumors china trial
I-Mab Reports Positive Interim Analysis from Phase 2/3 Study of its GM-CSF Antibody Plonmarlimab (TJM2) to Treat Patients with Severe COVID-19
Published: 2021-08-11 (Crawled : 13:00) - biospace.com/
IMAB | $1.8 160K
|
Health Technology
|
| O: -6.04%
H: 0.27%
C: -2.71%
covid phase 2 phase 2/3 positive antibody
I-Mab Announces IND Approval by FDA to Initiate Phase 1 Study for Protollin for the Treatment of Alzheimer's Disease
Published: 2021-07-30 (Crawled : 12:15) - prnewswire.com
IMAB | $1.8 160K
|
Health Technology
|
| O: -2.28%
H: 0.0%
C: 0.0%
disease alzheimer treatment fda phase 1 approval phase 2 phase 3 alzheimer’s alzheimer's disease alzheimer's
I-Mab Announces IND Acceptance for Phase 2 Clinical Trial of Efineptakin Alfa in Combination with PD-1 Therapy in China
Published: 2021-07-28 (Crawled : 12:00) - biospace.com/
IMAB | $1.8 160K
|
Health Technology
|
| O: 8.73%
H: 13.94%
C: 11.76%
phase 2 china therapy trial
TRACON Pharmaceuticals Presents Data from a Phase 1 Study of Uliledlimab (TJ004309) and Tecentriq® (Atezolizumab) at the American Society of Clinical Oncology Virtual Annual Meeting
Published: 2021-06-04 (Crawled : 13:15) - globenewswire.com
TCON | $1.875 3.02% 51K
|
Health Technology
|
| O: 2.95%
H: 1.11%
C: -6.05%
IMAB | $1.8 160K
|
Health Technology
|
| O: 0.01%
H: 5.28%
C: 2.46%
phase 1 phase 3 phase 2
I-Mab Announces First Patient Dosed in China Phase 2 Combination Trial of Lemzoparlimab with Azacitidine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome
Published: 2021-05-18 (Crawled : 13:00) - biospace.com/
IMAB | $1.8 160K
|
Health Technology
|
| O: 2.2%
H: 0.0%
C: -2.34%
phase 2 myeloid leukemia china leukemia trial syndros acute myeloid leukemia
I-Mab Announces Positive Topline Phase 2 Results for Olamkicept in Ulcerative Colitis
Published: 2021-04-26 (Crawled : 12:15) - biospace.com/
IMAB | $1.8 160K
|
Health Technology
|
| O: 0.6%
H: 1.23%
C: 0.22%
phase 2 positive phase 2 results results topline ulcerative colitis
Gainers vs Losers
| 85% | 15% |
Top 10 Gainers
MTTR | News M | $4.56 162.07% 21M
|
AGBA | $2.99 139.2% 64M
|
Finance
CZOO | $8.67 73.75% 23M
|
EDBL | News | $6.47 72.07% 1.9M
|
MTC | $2.21 41.67% 5.6M
|
Technology Services
OPRT | News | $3.12 38.67% 11M
|
Finance
PALI | $6.59 33.67% 23M
|
Manufacturing
VNRX | $0.7989 33.15% 3.2M
|
Health Technology
BTCM | $3.51 30.0% 730K
|
Arts, Entertainment, and Recrea...
MLEC | $1.81 29.29% 2.8M
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.